272 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Itau Unibanco Holding S.A.

Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 272 shares of the specialty pharmaceutical company’s stock, valued at approximately $29,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of JAZZ. Kovack Advisors Inc. grew its stake in Jazz Pharmaceuticals by 88.8% in the 1st quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after acquiring an additional 26,628 shares in the last quarter. John G Ullman & Associates Inc. bought a new position in Jazz Pharmaceuticals in the first quarter worth approximately $3,631,000. Swedbank AB purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $106,936,000. Dynamic Technology Lab Private Ltd purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $380,000. Finally, Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $110.76 on Monday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The stock has a fifty day moving average price of $110.79 and a 200-day moving average price of $111.00. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a market cap of $6.98 billion, a PE ratio of 22.84, a P/E/G ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Equities research analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Morgan Stanley cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Wells Fargo & Company lowered their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.